Optimizing Protein Expression: Folding, Solubility, and Compatibility

Successful recombinant protein production is not defined by yield alone. A protein must be correctly folded, soluble, biologically active, and compatible with its intended application. For research, drug development, diagnostics, and therapeutic production, protein quality determines whether an expressed product becomes a useful biomolecule or an unusable artifact.

Introduction

The success of recombinant protein production is not defined solely by yield. While producing a large quantity of protein is often a priority, the true measure of success lies in whether the protein is properly folded, biologically active, and suitable for downstream applications. A protein that is abundant but misfolded is essentially unusable. It may aggregate, fail to bind its target, or cause artifacts in experimental systems.

Similarly, proteins that lack essential post-translational modifications, also known as PTMs, can be unstable or inactive. In therapeutic contexts, they may also present immunogenic risks. Therefore, the real challenge of protein expression is not simply, “Can we produce it?” but rather, “Can we produce it in the right form, with the right properties, and in a way that is usable for its intended purpose?”

This perspective highlights the multidimensional nature of protein production. Beyond expression levels, success depends on structural integrity, functional competence, and biological compatibility. In this article, we focus on three key dimensions of protein quality: correct folding and PTMs, solubility and activity, and compatibility with mammalian systems. Together, these parameters determine whether a recombinant protein can move beyond the expression stage into functional assays, structural biology studies, drug development pipelines, or clinical applications.

Correct Protein Folding and Post-Translational Modifications

The Importance of Folding

Protein folding is a fundamental determinant of biological function. A misfolded protein is prone to aggregation, resulting in inclusion bodies in bacterial systems or unstable, heterogeneous products in eukaryotic cells. Misfolding not only reduces the yield of functional protein but also introduces variability that compromises reproducibility in research and consistency in biopharmaceutical production.

For instance, enzymes with improperly formed disulfide bonds may lose catalytic activity, and antibodies with misfolded domains may show altered binding specificity or rapid degradation. In such cases, high expression levels are meaningless if most of the product is misfolded and unusable.

The Role of PTMs

Beyond folding, PTMs significantly expand the functional repertoire of proteins. Glycosylation affects stability, receptor binding, and serum half-life. Phosphorylation regulates signaling activity. Acetylation and ubiquitination modulate protein turnover, while lipidation and prenylation influence membrane association.

Therapeutic proteins are especially dependent on PTMs. Antibodies, for example, rely on N-linked glycosylation of their Fc regions to mediate effector functions such as antibody-dependent cellular cytotoxicity, or ADCC. Cytokines and growth factors often require precise disulfide bond formation and proteolytic processing for biological activity.

Host System Influence on PTMs

Different expression systems vary dramatically in their ability to produce correct PTMs. Choosing the right host system is therefore one of the most important early decisions in recombinant protein development.

Practical Strategies for Ensuring Folding and PTMs

Researchers often combine construct design and process optimization to favor proper folding and modification. Useful strategies include:

• Including signal peptides to direct proteins into the endoplasmic reticulum and enhance disulfide bond formation.
• Using solubility-enhancing or stabilizing fusion partners, such as Fc-fusions, to improve folding and stability.
• Co-expressing molecular chaperones or foldases to assist with the correct assembly of complex proteins.
• Using glycoengineering platforms to tailor glycosylation profiles toward more human-like patterns.

Ultimately, ensuring correct folding and PTMs is not only a scientific goal but also a regulatory requirement in biopharmaceutical production, where product quality and safety are essential.

Improving Solubility and Activity

Solubility as the Foundation of Usability

Protein solubility is closely tied to stability and ease of purification. Insoluble proteins often require denaturation and refolding protocols, which are labor-intensive, inefficient, and frequently recover only a fraction of functional protein. Insolubility can also create serious bottlenecks in structural biology, high-throughput screening, and therapeutic development.

Strategies for Enhancing Solubility

A wide range of approaches can be applied to improve solubility during expression:

• Fusion tags: large tags such as maltose-binding protein, or MBP, and glutathione S-transferase, or GST, can increase solubility. Smaller tags such as SUMO or NusA can also aid folding while allowing easier removal.
• Chaperone co-expression: folding assistants such as GroEL/GroES in bacteria or BiP in mammalian cells can help proteins adopt correct conformations.
• Codon optimization: adjusting codons to match host tRNA availability can reduce ribosome stalling and misfolding.
• Optimized culture conditions: lower induction temperatures, reduced expression rates, or supplementation with stabilizing additives such as arginine or glycerol can increase the soluble fraction.
• Truncation or construct redesign: removing disordered or aggregation-prone regions can significantly improve solubility.

Impact on Biological Activity

A protein’s biological activity depends directly on its solubility and structural integrity. Soluble proteins are more likely to retain functional conformations, exhibit appropriate binding kinetics, and perform reliably in assays or therapeutic contexts.

For example, receptor extracellular domains expressed in soluble form can enable high-quality structural studies and binding assays. Conversely, aggregation-prone proteins often lose binding affinity or catalytic efficiency, leading to misleading experimental results. Expression hosts that provide more native-like folding environments, such as insect or mammalian cells, typically yield proteins with higher functional activity than bacterial systems.

Linking Solubility to Downstream Usability

Beyond expression and purification, solubility affects every stage of protein application. Soluble proteins support higher-quality crystal structures, reproducible kinetic data, and consistent formulation stability for therapeutic candidates. In biopharmaceutical manufacturing, solubility directly influences scalability, formulation, and long-term storage stability.

Enhancing Compatibility with Mammalian Systems

Application-Driven Requirements

As the biopharmaceutical landscape expands, compatibility with mammalian systems has become increasingly critical. Proteins intended for therapeutic use, diagnostics, or vaccine antigen development must not only be functional in vitro but also safe, biocompatible, and effective in vivo.

Immunogenicity and Safety Considerations

Proteins expressed in non-mammalian systems may carry unnatural modifications, truncated processing patterns, or misfolded domains that can trigger immune responses. For example, yeast-derived proteins may present non-human glycoforms that accelerate clearance or provoke immune recognition. These risks make compatibility with mammalian biology a central requirement for translational success.

Key considerations include:

• Achieving human-like glycosylation, including terminal sialylation.
• Ensuring stable disulfide bond formation to avoid misfolded or immunogenic species.
• Avoiding non-native chemical modifications that could compromise safety.

Advantages of Mammalian Cell Expression

Mammalian cells provide an intracellular environment that closely mirrors human physiology. This enables the production of proteins with:

• Native folding and assembly, including multimeric complexes.
• Authentic PTMs, such as N-linked glycosylation, phosphorylation, and proteolytic processing.
• Higher functional activity, particularly for membrane proteins, receptors, and antibodies.

CHO and HEK293 cells are the most widely used mammalian expression platforms for therapeutic proteins. They are supported by well-established regulatory frameworks and large-scale bioprocessing capabilities, making them useful for both preclinical and commercial applications.

Bridging Discovery and Translation

For exploratory research, bacterial or yeast systems may provide cost-effective early-stage material. However, proteins destined for translational studies often need to be re-expressed in mammalian systems to ensure biological compatibility. Transitioning from non-mammalian to mammalian expression should be considered an integral step in project planning rather than a last-minute adjustment.

Need Support with Protein Expression Optimization?

Conclusion and Outlook

Optimizing protein expression is a multidimensional challenge that extends far beyond maximizing yield. Correct folding and PTMs ensure biological relevance. Solubility and activity safeguard functionality. Compatibility with mammalian systems supports translational potential. Without these elements, recombinant proteins remain research artifacts rather than usable biomolecules.

Advances in synthetic biology, gene editing, and host engineering are reshaping the protein expression landscape. Glycoengineered yeasts and humanized insect cell lines are narrowing the gap with mammalian systems, offering cost-effective routes to near-human PTMs. Engineered bacterial strains that facilitate disulfide bond formation or incorporate unnatural amino acids are also broadening what is possible outside traditional mammalian platforms.

The future of protein expression lies in tailoring both the host and the production process to the specific requirements of each protein. Researchers and developers must ask not only, “Can we express this protein?” but also, “Can we express it in a form that is biologically relevant, stable, and safe?”

For both academic laboratories and biopharmaceutical companies, this shift in perspective is crucial. By prioritizing folding, solubility, and mammalian compatibility, protein science moves beyond the question of quantity and focuses on the true hallmark of success: producing proteins that are not just abundant, but genuinely fit for purpose.